Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rimegepant · Nurtec Odt, BMS-927711

Small molecule · Antagonist of calcitonin gene-related peptide receptor (CALCRL) · developed by Pfizer

Approved FDA, Feb 2020
PFE Developer

What is Rimegepant?

Rimegepant is a calcitonin gene-related peptide receptor antagonist that blocks CGRP signaling at its receptor. It is studied in acute treatment of migraine and in irritable bowel syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Nurtec Odt, BMS-927711
Drug type
Small molecule
Targets
calcitonin gene-related peptide receptor (CALCRL)
Mechanism
Antagonist of calcitonin gene-related peptide receptor (CALCRL)
Therapy area
Gastroenterology, Neurology
Developer
Pfizer (PFE)
FDA status
Approved as Nurtec Odt (February 27, 2020), NDA212728 · FDA label
UNII
997WVV895X

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Acute Treatment of MigraineIrritable Bowel Syndrome

Other drugs acting on CALCRL

More from Pfizer

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Rimegepant

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.